Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
Want to see AU:AGN full AI Analyst Report?
AGN Stock Chart & Stats
AU$0.18
<AU$0.01(0.81%)
At close: 4:00 PM EST
AU$0.18
<AU$0.01(0.81%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$0.85
Previous CloseN/A
Volume9.34K
Average Volume (3M)511.75K
Market Cap
AU$22.48M
Enterprise ValueAU$18.08M
Total Cash (Recent Filing)AU$10.56M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding128,456,710
10 Day Avg. Volume288,263
30 Day Avg. Volume511,745
Financial Highlights & Ratios
PEG Ratio-2.24
Price to Book (P/B)13.39
Price to Sales (P/S)30.16
P/FCF Ratio-16.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)AU$27.40M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially reduces solvency risk for a development-stage biotech and preserves strategic optionality. Without fixed interest obligations the company can prioritize R&D and partnership negotiations, extending runway and maintaining flexibility when seeking milestone or licensing-based funding.
Revenue Growth TrendSustained top-line growth demonstrates the firm can generate commercial or grant-derived income while progressing therapeutics. Growing revenue and gross profit that track it help stretch limited cash, validate aspects of the business model, and provide a foundation for partnerships or milestone-based deals over the medium term.
Focused Pipeline Addressing Unmet NeedA targeted lead asset addressing acute ischemic stroke tackles a large, persistent unmet medical need with clear clinical endpoints. Such focus can attract strategic pharma partners, grant funding and licensing interest, and supports a durable commercial opportunity if clinical development succeeds, given ongoing demand for stroke therapies.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business cannot self-fund development and will need recurring external financing. This structural cash burn raises dilution risk, can delay or constrain clinical programs if capital timing is poor, and forces management to balance spending against fundraising cycles.
Deep And Widening LossesVery large negative margins reflect operating costs far outstripping revenue and indicate the company is not near profitability. Persisting deep losses reduce retained capital, harm return metrics, and increase dependence on dilutive financing or partner deals to sustain R&D and clinical progression over the medium term.
Sharply Reduced Equity BaseA material decline in equity weakens the balance-sheet buffer and highlights prior losses or dilution. A smaller equity cushion increases vulnerability to adverse funding conditions, raises the probability of frequent capital raises, and may limit bargaining power with partners or potential acquirers during crucial clinical-development milestones.
Argenica Therapeutics Ltd News
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.13 and its highest was AU$0.85 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Argenica Therapeutics Ltd’s market cap is AU$22.48M.
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 305 days.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Argenica Therapeutics Ltd released its earnings results on Feb 10, 2026. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.03.
Is Argenica Therapeutics Ltd overvalued?
According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Overvalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 128,456,710 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Argenica Therapeutics Ltd reported an EPS of -AU$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenica Therapeutics Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.48%
12-Months-Change
Fundamentals
Return on Equity
-183.51%
Trailing 12-Months
Asset Growth
-66.25%
Trailing 12-Months
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.
Technical Analysis
Alterity Therapeutics
―
Race Oncology Ltd.
―
Nanollose Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Options Prices
Currently, No data available
---